sodium thiosulfate has been researched along with Minimal Disease, Residual in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boonstra, H; de Jong, RS; de Vries, EG; Mulder, NH; Sleijfer, DT; van der Graaf, WT; van der Zee, AG; Willemse, PH | 1 |
| Burger, CW; Hoekman, K; van Rijswijk, RE; Verheijen, RH; Vermorken, JB | 1 |
2 trial(s) available for sodium thiosulfate and Minimal Disease, Residual
| Article | Year |
|---|---|
Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.
Topics: Administration, Topical; Adult; Aged; Antioxidants; Cisplatin; Disease-Free Survival; Drug Therapy, Combination; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Cavity; Survival Rate; Thiosulfates | 1995 |
Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Survival Analysis; Thiosulfates; Treatment Outcome | 1997 |